JEFFREY LONG: Open Payments
NPI 1245326933 · HALEYVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$232 in 12 payments from 8 companies in 2025. Trend: 2023 $252 · 2024 $248 · 2025 $232
Food & beverage: $232
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 4 | $79 |
| ABBVIE INC. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Corcept Therapeutics | 1 | $19 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Novo Nordisk Inc | 1 | $14 |
Products named: Qelbree, FANAPT, LINZESS, Korlym, JOURNAVX, BREZTRI, UBRELVY, NEXLETOL.
Industry payments across AL — which companies pay providers there.
